Kura Oncology-backed Caspian plans Phase 1 study of diabetes drug candidate KO-7246
KURA•Caspian Therapeutics plans a Phase 1 program for its diabetes candidate KO-7246, an oral menin inhibitor. Kura Oncology announced an Oct. 13, 2026, investor webcast with Caspian to outline its launch and review preclinical data previously presented at the EASD annual meeting.
1. Planned clinical program
Caspian Therapeutics plans a Phase 1 program for KO-7246, shifting its menin-inhibitor work from oncology into diabetes-focused clinical development. The candidate is being developed as an oral treatment aimed at restoring beta-cell function and insulin production.
2. Investor webcast
Kura Oncology announced an Oct. 13, 2026, investor webcast with Caspian to outline Caspian’s launch and review preclinical KO-7246 data previously presented in an oral session at the EASD annual meeting.
